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Background. Chronic liver disease in human immunodeficiency virus (HIV)–infected patients is mostly caused
by hepatitis virus co-infection. Other reasons for chronic alanine aminotransferase (ALT) elevation are more difficult
to diagnose.
Methods. We studied the incidence of and risk factors for chronic elevation of ALT levels (greater than the
upper limit of normal at2 consecutive semi-annual visits) in participants of the Swiss HIV Cohort Study without
hepatitis B virus (HBV) or hepatitis C virus (HCV) infection who were seen during the period 2002–2008. Poisson
regression analysis was used.
Results. A total of 2365 participants were followed up for 9972 person-years (median age, 38 years; male sex,
66%; median CD4+ cell count, 426/mL; receipt of antiretroviral therapy [ART], 56%). A total of 385 participants
(16%) developed chronic elevated ALT levels, with an incidence of 3.9 cases per 100 person-years (95% confidence
interval [CI], 3.5–4.3 cases per 100 person-years). In multivariable analysis, chronic elevated ALT levels were
associated with HIV RNA level 1100,000 copies/mL (incidence rate ratio [IRR], 2.23; 95% CI, 1.45–3.43), increased
body mass index (BMI, defined as weight in kilograms divided by the square of height in meters) (BMI of 25–
29.9 was associated with an IRR of 1.56 [95% CI, 1.24–1.96]; a BMI 30 was associated with an IRR of 1.70
[95% CI, 1.16–2.51]), severe alcohol use (1.83 [1.19–2.80]), exposure to stavudine (IRR per year exposure, 1.12
[95% CI, 1.07–1.17]) and zidovudine (IRR per years of exposure, 1.04 [95% CI, 1.00–1.08]). Associations with
cumulative exposure to combination ART, nucleoside reverse-transcriptase inhibitors, and unboosted protease
inhibitors did not remain statistically significant after adjustment for exposure to stavudine. Black ethnicity was
inversely correlated (IRR, 0.52 [95% CI, 0.33–0.82]). Treatment outcome and mortality did not differ between
groups with and groups without elevated ALT levels.
Conclusions. Among patients without hepatitis virus co-infection, the incidence of chronic elevated ALT levels
was 3.9 cases per 100 person-years, which was associated with high HIV RNA levels, increased BMI, severe alcohol
use, and prolonged stavudine and zidovudine exposure. Long-term follow-up is needed to assess whether chronic
elevation of ALT levels will result in increased morbidity or mortality.
Human immunodeficiency virus (HIV)–associated mor-
bidity and mortality have decreased dramatically and
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continuously since the introduction of combination
antiretroviral therapy (cART) [1–3]. Because of im-
proved life expectancy, non–AIDS-defining diseases
and drug-related toxicities have emerged as a key is-
sue in the management of these patients. Liver-related
conditions are the most frequent cause of non–AIDS-
related death among the HIV-infected population [4].
The main causes of hepatopathy in HIV-infected per-
sons are hepatitis C virus (HCV) and hepatitis B virus
(HBV) infections.
Patients with HIV infection frequently have elevated
liver function test results [5]. The cause and clinical sig-
Chronic Elevation of ALT Level and HIV • CID 2010:50 (15 February) • 503
Figure 1. Patient flowchart for study of incidence and risk factors for
chronic elevation of alanine aminotransferase (ALT) levels in human im-
munodeficiency virus (HIV)–infected persons without hepatitis B virus
(HBV) or hepatitis C virus (HCV) co-infection.
nificance of these levels, particularly in the absence of chronic
viral hepatitis, often are unclear and make their assessment and
management difficult. Several studies have evaluated liver dis-
ease in patients with HCV and HBV co-infections, and most
examinations have focused on severe liver enzyme elevations
(defined as 3–5 times the upper limit of normal or more) [6–
8]. However, the majority of patients only have mild-to-mod-
erate increased liver enzyme levels. A recently published study
examined liver biopsy findings among HIV-infected patients
receiving antiretroviral therapy (ART) with unexplained chronic
elevated transaminase levels and found a high rate of histological
abnormalities: 22 (73%) of 30 patients had either liver fibrosis
and/or steatosis [9]. These results emphasize the importance of
chronic elevated ALT levels.
Two cross-sectional studies investigated predictors of liver
enzyme elevation in HIV-infected patients without HCV or
HBV infection. However, the first study excluded patients with
risk factors or evidence for nonalcoholic fatty liver disease and
alcohol abuse [10]. The second study used only a single elevated
alanine aminotransferase (ALT) value, which is subject to the
high intraindividual variability of liver tests. Furthermore, it is
not clear whether ALT values were collected concurrent with
clinical events or per protocol [11].
Because of the lack of data regarding elevated ALT levels
among HIV-positive patients without chronic viral hepatitis,
we studied the incidence of and risk factors for chronic ALT
elevation as a sign for chronic liver disease in a large prospective,
longitudinal multicenter cohort.
METHODS
Study population. The Swiss HIV Cohort study (SHCS) is
an ongoing, prospective cohort study that was established in
1988 and that continuously enrolls and observes HIV-infected
individuals aged 16 years at 5 university outpatient clinics, 2
large cantonal hospitals, affiliated regional hospitals, and private
practices [12]. Information and laboratory values, including
liver enzyme levels, are collected according to defined criteria
at registration and follow-up visits every 6 months. The study
was approved by local ethics review boards, and written in-
formed consent was obtained from all participants.
For this analysis, we included SHCS participants without
HBV and HCV infection and at least 3 consecutive semiannual
visits with ALT determinations who were seen after 1 January
2002, which was the date on which ALT values were regularly
collected in the SHCS. The last follow-up visit was in December
2008. Patients with prevalent elevated ALT levels at the time
of the baseline visit were excluded from the study. Baseline visit
was defined as the first visit after 1 January 2002.
Definitions. Chronic ALT elevation was defined as an ALT
level greater than the upper limit of normal at 2 or more
consecutive semiannual visits. HCV infection was defined as
present in patients who were seropositive for HCV or who had
test results positive for HCV RNA. HBV infection was defined
as present in patients who were positive for hepatitis B surface
antigen or hepatitis B e antigen or hepatitis B core antibodies
or who had detectable HBV DNA during the study period.
Body mass index (BMI, defined as weight in kilograms divided
by the square of height in meters) was stratified into !18.5
(underweight), 18.5–24.9 (normal), 25–29.9 (overweight), and
30 (obese) [13]. Central obesity was defined according to the
new worldwide definition [14], with sex- and ethnicity-specific
waist circumference cut-off values. Hypercholesterolemia and
hypertriglyceridemia were defined as present in patients with
total cholesterol 16.5 mmol/L and triglycerides 11.7 mmol/L,
respectively. Diabetes mellitus was diagnosed according to the
criteria of the Expert Committee on the Diagnosis and Clas-
sification of Diabetes Mellitus [15], with confirmed plasma
glucose level cut-off values of 17.0 mmol/L (fasting) and 111.1
mmol/L (nonfasting). Elevated blood pressure was defined as
present in patients with diastolic blood pressure 85 mmHg
or systolic blood pressure 130 mmHg. Smoking status was
stratified into never, former, and current smoking. Alcohol use
was stratified into severe use (female patients, 140 g/day; male
Table 1. Baseline Characteristics of 2365 Patients with and Patients without Incident Chronic Elevation of Alanine
Aminotransferase (ALT) Levels during Follow-Up
Variable
All subjects
(n p 2365)
Chronic elevation of ALT during follow-up
P
Yes
(n p 385)
No
(n p 1980)
Sex
Female 800 (34) 138 (36) 662 (33) .4
Male 1565 (66) 247 (64) 1318 (67)
Age, median years (IQR) 38 (33–45) 40 (35–47) 38 (33–45) !.001
Race
White 1989 (84) 337 (88) 1652 (83) .06
Black 234 (10) 23 (6) 211 (11)
Hispanic 62 (3) 12 (3) 50 (3)
Asian 77 (3) 12 (3) 65 (3)
Other 3 (0.1) 1 (0.3) 2 (0.1)
Mode of HIV infection
Heterosexual sex 1242 (53) 217 (56) 1025 (52) .1
MSM 982 (42) 150 (39) 832 (42)
IDU 26 (1) 6 (2) 20 (1)
Other 115 (5) 12 (3) 103 (5)
Date of HIV infection diagnosis, median date (range) May 2000 (Apr 1996–
May 2004)
Sep 1997 (May 1994–
Jan 2001)
Mar 2001 (Sep 1996–
Oct 2004) !.001
Baseline CD4+ cell count
Median cells/mL (IQR) 426 (269–614) 492 (313–695) 420 (264–597) !.001
0–199 cells/mL 340 (14) 36 (9) 304 (15)
200–499 cells/mL 1105 (47) 159 (41) 946 (48)
500 cells/mL 917 (39) 189 (49) 728 (37)
Nadir CD4+ cell count, median cells/mL (IQR) 249 (119–403) 216 (99–361) 256 (124–409) .002
HIV RNA level in ART-naive patients, median log10
copies/mL (IQR) 4.5 (3.9–5.1) 4.5 (4.0–5.0) 4.5 (3.9–5.1) .9
ART-treated patients with undetectable HIV RNA
level 1649 (70) 239 (62) 1410 (71) !.001
Peak HIV RNA level, median log10 copies/mL (IQR) 4.9 (4.1–5.4) 4.9 (4.3–5.3) 4.9 (4.1–5.4) 1.99
Previous clinical AIDS 402 (17) 81 (21) 321 (16) .02
BMI, median value (IQR) 23 (21–25) 24 (22–26) 23 (21–25) !.001
!18.5 98 (4) 13(3) 85 (4)
18.5–24 1587 (68) 226 (59) 1361 (70)
25–29 539 (23) 119 (31) 420 (21)
30 113 (5) 22 (6) 91 (5)
Central obesitya 651 (28) 146 (38) 505 (26) !.001
Lipodystrophy
Atrophy 310 (13) 76 (20) 234 (12) !.001
Fat accumulation 316 (13) 88 (23) 228 (12) !.001
Diabetes mellitus 52 (2) 6 (2) 46 (2) .3
Total cholesterolb
Median mmol/L (IQR) 4.9 (4.2–5.8) 5.3 (4.5–6.4) 4.8 (4.1–5.7) !.001
16.5 mmol/L 275 (12) 78 (21) 197 (10)
HDL cholesterolb
Median mmol/L (IQR) 1.2 (1.0–5.8) 1.2 (1.0–6.4) 1.2 (1.0–5.7) .8
!1.0 mmol/L (male patients) or !1.3 mmol/L (fe-
male patients) 885 (39) 144 (39) 741 (39)
Triglyceridesb
Median mmol/L (IQR) 1.6 (1.0–2.6) 2.0 (1.3–3.6) 1.5 (1.0–2.4) !.001
11.7 mmol/L 1051 (46) 215 (58) 836 (44)
Arterial hypertensionc 1042 (44) 192 (50) 850 (43) .01
Smoking statusd
Never 1274 (54) 210 (55) 1064 (54) .03
Former 103 (4) 26 (7) 77 (4)
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Table 1. (Continued.)
Variable
All subjects
(n p 2365)
Chronic elevation of ALT during follow-up
P
Yes
(n p 385)
No
(n p 1980)
Current 977 (42) 149 (39) 828 (42)
Active IDUd 6 (0.3) 0 (0) 6 (0.3) .3
Alcohol consumptione
Mean g/day (IQR) 14.4 (6–20) 18.4 (6–20) 13.7 (6–20) .4
None 646 (27) 108 (28) 538 (27) .004
Light 1393 (59) 206 (54) 1187 (60)
Moderate 220 (9) 42 (11) 178 (9)
Severe 106 (4) 29 (8) 77(4)
ART
Naive 812 (34) 74 (19) 738 (37) !.001
Currently interrupted 228 (10) 37 (10) 191 (10)
Receiving treatment 1325 (56) 274 (71) 1051 (53)
Duration, median years (IQR) 1.2 (0–5.0) 3.6 (0.4–5.7) 0.6 (0–4.8) !.001
NOTE. Data are no. (%) of patients, unless otherwise indicated. ALT, alanine aminotransferase; BMI, body mass index, calculated as the
weight in kilograms divided by the square of height in meters; HDL, high density lipoprotein; IDU, injection drug use; MSM, men who have
sex with men.
a For central obesity definition, see Methods.
b Normal values are as follows: total cholesterol !6.5 mmol/L, HDL cholesterol 11 mmol/L for male patients and 11.3 mmol/L for female
patients, and triglycerides !1.7 mmol/L.
c For arterial hypertension definition, see Methods.
d Smoking and active IDU within the 6 months prior to baseline visit.
e For alcohol consumption, we used the highest consumption value measured.
patients, 160 g/day), moderate (female patients, 20–40 g/day;
male patients, 40–60 g/day) and light use (female patients, !20
g/day; male patients, !40 g/day) according to the World Health
Organization definition.
Statistical analysis. We defined the incidence of chronic
ALT elevation as the number of cases of chronic ALT elevation
divided by the total number of person-years of follow-up
(PYFU). Associations between incident chronic ALT elevation
and demographic, clinical, anthropometric, and drug-related
covariables were analyzed in univariable and multivariable Pois-
son regression models. Fixed covariables were sex, ethnicity,
mode of HIV acquisition, and HIV Centers for Disease Control
and Prevention (CDC) disease stage. For alcohol consumption,
we used the highest consumption value measured, even when
it was reported by patients after development of chronic ele-
vation of ALT, assuming that drinking habits remain steady.
Time-updated covariables were age, smoking status, BMI, cen-
tral obesity, lipodystrophy, hypercholesterolemia, hypertrigly-
ceridemia, diabetes mellitus, arterial hypertension, CD4+ cell
count, HIV RNA level, and continuous and categorical years
of exposure to cART, the different drug classes (nucleoside re-
verse-transcriptase inhibitors [NRTIs], protease inhibitors [PIs]
and nonnucleoside reverse-transcriptase inhibitors [NNRTIs]),
and individual drugs. We focused on cumulative drug exposure
and did not analyze current drug exposure. The end point of
chronic ALT elevation is not suitable to detect acute effects of
current drug exposure. In patients with an acute hepatotoxicity,
the suspected drugs were changed immediately to a less toxic
regimen, and persistent ALT elevation may be attributed to the
new treatment, causing reverse causality problems [16]. We first
built a multivariable model with demographic, clinical, and
anthropometric covariables, including alcohol consumption.
Next, we included cumulative exposure to the different drug
classes and individual drugs. To disentangle the strong asso-
ciation with stavudine from associations with the other drugs,
we repeated the multivariable models with inclusion of sta-
vudine exposure. We did not formally check for interactions
because of the high number of potential combinations but
checked for effect modifications during the model building
process. Characteristics of different patient groups were com-
pared using x2 tests or Wilcoxon rank-sum tests; for mortality,
Kaplan-Meier estimates and log-rank test were used. All anal-
yses were performed using Stata software, version 10.1 (Stata).
RESULTS
Patient characteristics. Of 8435 SHCS participants seen be-
tween 1 January 2002 and 31 December 2007, 3255 (39%) were
HBV and HCV negative. Of these patients, we excluded 760
with !3 follow-up visits, gaps in follow-up, or missing data. A
total of 130 patients (5%) were excluded because of preexisting
elevated ALT levels at time before or at time of baseline visit
(these patients had a significantly longer median period of ex-
posure to ART, compared with that for patients without prev-
Table 2. Univariable and Multivariable Poisson Regression of Demographic, Clinical,
and Anthropometric Covariables Potentially Affecting the Risk of Developing Chronic
Elevation of Alanine Aminotransferase (ALT) Levels Based on 2365 Individuals with 385
Events Followed Up for 9972 Person-Years
Variable
IR per 1000
PYFU (95% CI)
IRR univariable
models (95% CI)
IRR multivariable
model a (95% CI)
Sex
Female 40 (33–47) 1 1
Male 38 (34–43) 0.96 (0.78–1.19) 0.84 (0.63–1.11)
Age, per 10 years 1.06 (0.97–1.17) 1.0 (0.90–1.11)
Race
White 40 (36–44) 1 1
Black 24 (16–36) 0.60 (0.39–0.91) 0.52 (0.33–0.82)
Hispanic 50 (28–88) 1.25 (0.70–2.23) 1.14 (0.64–2.06)
Asian 42 (24–73) 1.05 (0.59–1.86) 1.11 (0.62–2.01)
Unknown 67 (9–473) 1.67 (0.23–11.9) 2.22 (0.31–16.0)
Mode of HIV infection
Heterosexual sex 40 (35–46) 1 1
MSM 38 (32–44) 0.94 (0.76–1.15) 1.03 (0.79–1.36)
IDU 47 (21–104) 1.16 (0.52–2.61) 1.38 (0.61–3.14)
Other 25 (14–44) 0.62 (0.35–1.11) 0.62 (0.35–1.12)
CD4+ cell count, cells/mL
0–199 34 (22–53) 0.80 (0.49–1.27) 0.61 (0.37–1.01)
200–499 35 (30–41) 0.81 (0.66–0.99) 0.73 (0.58–0.91)
500 43 (38–49) 1 1
Nadir CD4+ cell count, cells/mL
0–199 41 (36–47) 1.01 (0.70–1.45) 1.33 (0.89–1.99)
200–499 36 (30–42) 0.88 (0.61–1.26) 1.02 (0.70–1.50)
500 41 (29–57) 1 1
HIV RNA level
0–10,000 copies/mL 37 (33–42) 1 1
10,000–100,000 copies/mL 39 (29–52) 1.05 (0.77–1.43) 1.22 (0.88–1.70)
100,000 copies/mL 69 (46–103) 1.85 (1.22–2.80) 2.23 (1.45–3.43)
BMI
!18.5 22 (12–41) 0.66 (0.35–1.24) 0.64 (0.34–1.21)
18.5–24 34 (30–38) 1 1
25–29 51 (43–61) 1.52 (1.22–1.89) 1.56 (1.24–1.96)
30 57 (40–81) 1.69 (1.16–2.45) 1.70 (1.16–2.51)
Smoking status
Never 40 (34–47) 1 1
Former 47 (39–57) 1.17 (0.91–1.50) 1.04 (0.79–1.38)
Current 33 (28–39) 0.81 (0.64–1.02) 0.79 (0.62–1.00)
Alcohol consumption
None 40 (33–48) 1 1
Light 35 (31–40) 0.89 (0.70–1.12) 0.91 (0.71–1.16)
Moderate 44 (32–59) 1.10 (0.77–1.57) 1.13 (0.78–1.62)
Severe 67 (46–96) 1.68 (1.12–2.53) 1.83 (1.19–2.80)
NOTE. BMI, body mass index, calculated as weight in kilograms divided by the square of height in
meters; CI, confidence interval; IDU, injection drug use; IR, incidence rate; IRR, incidence rate ration;
MSM, men who have sex with men; PYFU, person-years of follow-up.
a Adjusted for all variables listed. Age, CD4+ cell count, nadir CD4+ cell count, HIV RNA level, BMI,
and smoking status were analyzed as time-updated covariables. For alcohol consumption, we used the
highest consumption value measured.
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Table 3. Multivariable Poisson Regression of Combination Antiretroviral Therapy (cART), Different Antiretroviral Classes, and Single
Drugs (Time-Updated Cumulative Exposure) Potentially Affecting the Risk of Developing Chronic Elevated Alanine Aminotransferase
(ALT) Levels
Antiretroviral therapy or
individual antiretroviral
drugs per year exposure
IRR from
univariable models (95% CI) P
IRR from
multivariable modelsa (95% CI) P
IRR from multivariable
models including sta-
vudine exposureb
(95% CI) P
cART 1.04 (1.01–1.07) .015 1.05 (1.01–1.08) .015 1.00 (0.96–1.04) .9
NRTI 1.05 (1.02–1.08) !.001 1.06 (1.03–1.09) !.001 1.03 (0.99–1.07) .1
Unboosted PI 1.06 (1.02–1.11) .002 1.07 (1.02–1.11) .003 1.03 (0.98–1.07) .3
Boosted PI 1.02 (0.97–1.07) .5 1.01 (0.96–1.07) .6 0.98 (0.93–1.04) .5
NNRTI 1.03 (0.98–1.08) .2 1.03 (0.98–1.08) .2 1.01 (0.96–1.06) .6
NRTI, by drug
Stavudine 1.11 (1.07–1.16) !.001 1.12 (1.07–1.17) !.001 … …
Zidovudine 1.02 (0.99–1.05) .3 1.02 (0.98–1.06) .3 1.04 (1.00–1.08) .028
Didanosine 1.06 (1.00–1.12) .045 1.07 (1.01–1.13) .024 1.03 (0.97–1.09) .4
Lamivudine 1.04 (1.01–1.07) .019 1.04 (1.00–1.08) .039 1.02 (0.98–1.05) .4
Abacavir 0.10 (0.94–1.05) .9 0.99 (0.93–1.04) .7 0.98 (0.93–1.04) .5
Emtricitabine 0.44 (0.25–0.77) .004 0.45 (0.25–0.78) .005 0.47 (0.27–0.82) .008
Tenofovir 0.96 (0.86–1.06) .4 0.96 (0.86–1.07) .5 0.93 (0.84–1.04) .2
PI, by drug
Nelfinavir 1.07 (1.02–1.12) .006 1.07 (1.02–1.12) .007 1.03 (0.98–1.09) .2
Lopinavir 1.02 (0.95–1.11) .6 1.02 (0.94–1.11) .7 1.01 (0.93–1.10) .8
Saquinavir 1.05 (0.97–1.13) .2 1.04 (0.96–1.12) .3 0.97 (0.89–1.05) .4
Indinavir 1.05 (0.98–1.12) .2 1.03 (0.97–1.10) .3 1.00 (0.93–1.07) 1.99
Atazanavir 0.91 (0.76–1.09) .3 0.89 (0.74–1.07) .2 0.87 (0.73–1.04) .1
Ritonavir, full dose 0.98 (0.87–1.11) .7 0.98 (0.87–1.12) .8 0.95 (0.83–1.09) .5
NNRTI, by drug
Efavirenz 0.99 (0.94–1.05) .8 0.99 (0.94–1.05) .8 0.98 (0.92–1.04) .5
Nevirapine 1.10 (1.02–1.18) .012 1.10 (1.02–1.18) .013 1.07 (0.99–1.15) .07
NOTE. IRR, incidence rate ratio; NNRTI nonnucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse-transcriptase inhibitor; PI, protease inhibitor.
a The different drugs were individually adjusted for the covariables listed in Table 2.
b The different drugs were individually adjusted for the covariables listed in Table 2 and the cumulative exposure to stavudine per year.
alent elevated ALT levels, particularly to stavudine and zido-
vudine; data not shown). The present study is thus based on
2365 HIV-infected individuals with normal ALT values at base-
line visit (Figure 1).
Baseline characteristics of patients with and patients without
incident chronic elevation of ALT during follow-up are sum-
marized in Table 1. The proportion of men was 66%. The
median age of the patients was 38 years, and 84% were white.
Baseline and nadir (ie, lowest ever) CD4+ lymphocyte counts
were 426 and 249 cells/mL, respectively. Median duration of
antiretroviral therapy was 1.2 years; 34% of patients were treat-
ment naive, 10% had interrupted ART, and 56% were receiving
treatment. HIV RNA levels were below the level of detection
in 70% of ART-treated patients. Several of the baseline variables
were associated with the development of chronic ALT elevation.
During the follow-up period, 385 patients (16%) developed
chronic elevated ALT levels during 9972 PYFU, resulting in an
incidence of 3.9 cases per 100 PYFU (95% CI, 3.5–4.3 cases
per 100 PYFU). The incidence significantly decreased over time,
with an IRR of 0.84 (95% CI, 0.79–0.88) per year. The incidence
was 5.6 cases per 100 PYFU (95% CI, 4.7–6.8 cases per 100
PYFU) during the period 2002–2003, 4.5 cases per 100 PYFU
(95% CI, 3.8–5.3 cases per 100 PYFU) during the period 2004–
2005, and 2.8 cases per 100 PYFU (95% CI, 2.3–3.3 cases per
100 PYFU) during the period 2006–2008.
Univariable and multivariable models. The results of the
univariable and multivariable Poisson regression analyses are
displayed in Table 2. Black ethnicity and CD4+ cell count of
200–500 cells/mL, compared with 1500 cells/mL, were negative
predictors for chronic elevated ALT levels. An HIV RNA level
1100,000 copies/mL was a strong positive predictor. There was
no effect of age, sex, HIV transmission category, CDC stage C,
nadir CD4+ cell count, smoking, and receipt of medications
other than ART, except lipid-lowering drugs, on the incidence
of chronic elevated ALT levels. Results of the univariable and
multivariable model were identical.
Association of metabolic parameters and chronic elevated
ALT levels. In univariable and multivariable analysis, in-
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Figure 2. Incidence rate ratios (IRRs) and 95% confidence intervals (CIs) for the development of new chronic elevation of alanine aminotransferase
(ALT) levels based on 385 events among 2365 participants with 9972 person years of follow-up. Shown are associations with receipt of combination
antiretroviral therapy (cART) and specific drug classes for 0 years, 2 years, 5 years, and 15 years. Left panel, multivariable models were individually
adjusted for the variables listed in Table 2. Right panel, multivariable models were individually adjusted for the variables listed in Table 2 and cumulative
exposure to stavudine. cART, combination antiretroviral therapy; NNRTI, nonnucleoside reverse-transcriptase inhibitor; NRTI, nucleoside reverse-
transcriptase inhibitor; PI, protease inhibitor; PI/r, ritonavir-boosted protease inhibitor.
creased BMI was significantly associated with chronic elevated
ALT levels (BMI of 25–29.9 was associated with an IRR of 1.56
[95% CI, 1.24–1.96]; BMI of 30 was associated with an IRR
of 1.70 [95% CI, 1.16–2.51]). Other risk factors for nonalco-
holic fatty liver disease [17, 18], including central obesity (IRR,
1.66; 95% CI, 1.36–2.03), lipoatrophy (IRR, 1.50; 95% CI, 1.19–
1.90), lipohypertrophy (IRR, 1.79; 95% CI, 1.43–2.23), hyper-
cholesterolemia (IRR, 1.63; 95% CI, 1.25–2.12), hypertrigliceri-
demia (IRR, 1.75; 95% CI, 1.43–2.15), use of lipid-lowering
drugs (IRR, 1.48; 95% CI, 1.11–1.98), and arterial hypertension
(IRR, 1.27; 95% CI, 1.04–1.55) were also predictors for chronic
elevated ALT levels in the univariable analyses, but these var-
iables were not included in the multivariable model because of
collinearity or the same causal pathway. Diabetes mellitus was
not statistically significant in the univariable analysis (IRR, 1.05;
95% CI, 0.59–1.87).
Association of alcohol use and chronic elevated ALT levels.
We analyzed the contribution of severe, moderate, and light
alcohol use to the development of elevated ALT levels in uni-
variable and multivariable models. Only severe alcohol use was
significantly associated with the incidence of elevated ALT lev-
els; moderate and light alcohol use showed no association.
Association of ART and chronic elevated ALT levels.
Associations of ART and chronic elevated ALT are shown in
Table 3 and Figure 2. Cumulative exposure (as a continuous
variable) to cART, NRTIs, and unboosted PIs increased the risk
of developing chronic elevated ALT in the univariable and mul-
tivariable model. Among individual antiretroviral drugs, the
strongest relationship with chronic elevated ALT levels was with
exposure to stavudine (IRR per year of exposure, 1.12; 95%
CI, 1.07–1.17; ). There was also a significant effect ofP ! .001
didanosine, lamivudine, nelfinavir, and nevirapine. However,
after adjustment for stavudine exposure, none of the antiret-
roviral classes or individual drugs remained significant. After
adjusting to stavudine, exposure to zidovudine was associated
with an increased risk of chronic ALT elevation, whereas ex-
posure to emtricitabine was conversely associated (Table 3).
When we stratified cumulative exposure into categorical vari-
ables (never, !2 years, 2–5 years, 15 years), cART, NRTI, and
unboosted PI exposure 2 years were a risk factor for chronic
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elevated ALT levels but did not remain predictive after adjust-
ment for stavudine exposure. NNRTI exposure of !5 years
duration showed an association with elevated ALT level (Figure
2). Nevirapine as a categorical variable was a risk factor for
chronic ALT elevation with short-term use (!2 years) with and
without adjustment for stavudine exposure (data not shown).
Sensitivity analyses. In separate models, we analyzed 3
consecutive elevated ALT values instead of 2 at semiannual
visits. The incidence for 3 consecutive elevated ALT values was
2.1 cases per 100 PYFU (95% CI, 1.9–2.4 cases per 100 PYFU)
in 228 patients with 10,628 PYFU. Univariable and multivar-
iable evaluations with this modified definition yielded consis-
tent results.
Clinical outcome. Four (1.0%) of the patients with elevated
ALT levels versus 30 (1.5%) of the patients without elevated
ALT levels died. Five-year mortality did not differ significantly
between patients with and patients without development of
chronic elevated ALT levels: 0.3% (95% CI, 0.04%–2.2%) versus
1.6% (95% CI, 1.1%–2.5%), respectively ( ). ReasonsPp .14
for death in the elevated ALT group were suicide, myocardial
infarction, bladder cancer, and acute peritonitis.
At last visit, 86.0% of the patients with elevated ALT levels
versus 78.8% of those with normal ALT levels were receiving
ART, 9.6% versus 10.8% had interrupted ART, and 4.4% versus
10.4% were ART naive ( ). For those who were re-Pp .001
ceiving ART, HIV load was suppressed equally in both groups
(87% vs 85%), and the median CD4+ cell count was 593 cells/
mL (range, 430–767 cells/mL) versus 525 cells/mL (range, 384–
714 cells/mL). Number of treatment changes per year, including
treatment switches and interruptions, did not differ between
the 2 groups (data not shown).
DISCUSSION
In this large longitudinal cohort analysis, the incidence of
chronic elevated ALT levels (ie, elevation for 6 months) was
3.9 cases per 100 PYFU. In adjusted analyses, increased BMI,
high alcohol use, and prolonged exposure to stavudine and
zidovudine were associated with chronic ALT elevation.
In contrast to cross-sectional analyses, in which the temporal
sequence of exposure and outcome is often not ascertained,
the longitudinal design chosen for our study should allow for
a more precise determination of predictors. To our knowledge,
there are no data available for the incidence of ALT elevation
in an HIV-infected population without chronic viral hepatitis.
However, several studies have reported on the prevalence of
elevated ALT levels in the general population and among HIV-
infected persons. The large National Health and Nutrition Ex-
amination Survey (NHANES) III study, representing a civilian
noninstitutionalized population in the United States, found a
prevalence of 13.5% in HCV- and HBV-negative individuals
[19]. A German cohort study of orthopedic surgery patients
without chronic viral hepatitis noted a prevalence of 11.3%
[20] and in HIV-infected persons without viral hepatitis the
prevalence was in the same range with 15% [11]. These figures
are in accordance with our study with a prevalence of 13.2%
in a single ALT measurement at baseline (data not shown).
Our results confirm that the main causes of chronic liver
disease in HIV-infected patients without hepatitis B and C co-
infections are alcohol consumption, non-alcoholic fatty liver
disease (NAFLD) and antiretroviral drugs.
Several mechanisms of antiretroviral drugs resulting in liver
enzyme elevation have been postulated: mitochondrial toxicity
related to NRTIs, hypersensitivity, primarily caused by nevi-
rapine and metabolic injury, mainly associated to PIs through
their effects on metabolic factors [21]. In our analysis the stron-
gest relationship with the development of chronic elevated ALT
was with exposure to stavudine. Furthermore, with decreasing
stavudine use over time, the incidence of ALT elevation was
significantly decreasing during the observation period. The as-
sociation with this dideoxynucleoside analogues does not sur-
prise, as it is a strong inhibitor of mitochondrial DNA synthesis
resulting in a high mitochondrial toxicity [22]. Stavudine has
been implicated in the development of hepatic steatosis [23,
24]. The other dideoxynucleoside analogues, didanosine, has
recently been postulated as a cause for noncirrhotic portal hy-
pertension [25, 26], but in our study showed only a trend with
chronic elevated ALT. Nevirapine, known to cause early acute
hepatitis produced by a hypersensitivity mechanism [27], was
associated with elevated ALT as a categorical variable during
the first 2 years of exposition (data not shown).
It was to be expected that the traditional risk factors for non-
alcoholic fatty liver disease, namely increased BMI, central obe-
sity, lipodystrophy and dyslipidemia, as well as severe alcohol
consumption were associated with the development of elevated
ALT, a surrogate marker for hepatic steatosis [28]. Hepatic
steatosis is common in HIV-infected persons with metabolic
abnormalities with [23, 29] and without HCV co-infection [9,
30, 31]. In addition to the metabolic aberrations and severe
alcohol use, ART-related mitochondrial toxicity might also con-
tribute to hepatic steatosis, but hepatic steatosis might also be
a predisposing factor for antiretroviral hepatotoxicity [32]. This
needs to be further evaluated.
Our finding of black ethnicity as a negative predictor for
ALT elevation is in agreement with other investigations, which
found an inverse association of black ethnicity and NAFLD in
the general population [33] and among HIV-infected patients
[24, 31, 34]. However, it is unknown whether ethnic or genetic
factors may play a role in protecting from hepatopathy.
Similar to 2 other reports, our study found that a high HIV
load was an independent risk factor for the development of
chronic elevated ALT levels [11] and steatosis [29]. The mech-
anisms associated with this observation are possibly attributa-
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ble to immune activating and pro-apoptotic effects of HIV on
hepatocytes, which have been demonstrated in several studies
(reviewed in [35]).
The NHANES III study found a strong association between
liver-related mortality and elevated ALT levels in a cohort of
patients from the general population without chronic viral hep-
atitis [19]. In addition, elevated ALT levels in HIV-infected
patients reported as adverse events cause by ART was associated
with a higher mortality independently from chronic viral hep-
atitis co-infection [36]. This is in contrast to our data, which
did not show a higher mortality, presumably because of a rel-
atively short observation period.
The strengths of this study are the large number of patient-
years with prospectively collected anthropometric, laboratory,
and clinical data, including the assessment of alcohol use. ALT
determination was according to study protocol and was not
triggered by symptoms or clinical events. Limitations include
the use of a laboratory surrogate marker (ie, elevated ALT level)
as a sign for hepatopathy, instead of examination of liver tissue.
However, liver biopsies were not feasible in this large epide-
miologic study, and elevated ALT level is considered to be a
highly specific indicator for liver injury, which is the most
commonly used marker for chronic liver disease. Regarding the
high intraindividual variability of liver tests [37], we used 2
consecutive elevated ALT values over a period of 6 months.
Because we excluded patients with preexisting elevated ALT
levels at baseline (these patients had longer exposure to ART,
particularly to NRTIs), the incidence of chronic ALT elevation
in patients receiving ART may be underestimated. We did not
consider hemochromatosis, autoimmune hepatitis, or infec-
tions other than HCV and HBV infection, such as hepatitis A
virus, cytomegalovirus, or Epstein-Barr virus infections, but as
they are very infrequent causes of chronic elevation of ALT
levels among HIV-infected persons, no significant influence on
the analysis would be expected. Finally, results from cohort
analyses need to be interpreted with caution because of the
potential for unmeasured confounding.
In summary, we evaluated the incidence of and factors as-
sociated with chronic elevated ALT levels among HIV-infected
patients without HBV and HCV co-infection. Chronic ALT
elevation is frequent in this population. Besides those factors
classically recognized as predisposing to hepatic steatosis in
HIV-negative individuals, such as being overweight and hav-
ing elevated alcohol consumption, high HIV RNA levels and
exposure to stavudine and zidovudine were associated with
chronic elevated ALT levels. Our findings may have clinical
implications, given that several studies suggest an association
of chronic elevated ALT levels and an increased mortality [19,
36] and a high rate of severe histological abnormalities [9].
Early recognition and management of metabolic factors (eg,
being overweight or having dyslipidemia), prevention or treat-
ment of severe alcohol use, early initiation of cART if the HIV
RNA level is high, and avoidance of stavudine and zidovudine
are recommended in patients with chronically elevated ALT
levels. Long-term follow-up is needed to assess whether chronic
ALT elevation will result in increased morbidity or mortality.
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